Teva Pharmaceutical Indus... (TEVA)
15.49
-0.20 (-1.27%)
At close: Mar 27, 2025, 3:59 PM
15.63
0.90%
After-hours: Mar 27, 2025, 08:00 PM EDT
Teva Pharmaceutical Industries Limited Revenue Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 |
---|---|---|
Distribution Service Revenue | 390M | 382M |
Distribution Service Revenue Growth | +2.09% | n/a |
License Revenue | 45M | 36M |
License Revenue Growth | +25.00% | n/a |
Product and Service, Other Revenue | 102M | 106M |
Product and Service, Other Revenue Growth | -3.77% | n/a |
Product Revenue | 3.79B | 3.64B |
Product Revenue Growth | +4.23% | n/a |
Revenue by Geography
Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|---|---|
Europe Revenue | 4.84B | 4.46B | 4.81B | 4.74B | 4.77B | 5.15B |
Europe Revenue Growth | +8.57% | -7.32% | +1.50% | -0.71% | -7.43% | n/a |
North America Revenue | 8.12B | 5.83B | 6.39B | 6.9B | 6.94B | 7.84B |
North America Revenue Growth | +39.25% | -8.76% | -7.36% | -0.56% | -11.44% | n/a |
Operating Expense Breakdown
Quarter | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 952M | 924M | 939M | 886M | 902M | 844M | 910M | 842M | 838M | 822M | 907M | 880M | 908M | 888M | 857M | 875M | 1.01B | 884M | 861M | 917M | 1.02B | 880M | 962M | 940M | 1.14B | 1.05B | 1.03B | 1.1B | 1.36B | 1.19B | 1.23B | 1.21B | 1.44B | 1.25B | 1.26B | 1.14B | 1.21B | 1.1B | 1.19B | 1.23B |
Selling, General, and Administrative Revenue Growth | +3.03% | -1.60% | +5.98% | -1.77% | +6.87% | -7.25% | +8.08% | +0.48% | +1.95% | -9.37% | +3.07% | -3.08% | +2.25% | +3.62% | -2.06% | -13.37% | +14.25% | +2.67% | -6.11% | -10.45% | +16.36% | -8.52% | +2.34% | -17.62% | +8.46% | +2.53% | -6.73% | -18.94% | +14.03% | -3.41% | +2.07% | -16.18% | +15.20% | -1.03% | +10.50% | -5.30% | +10.13% | -7.51% | -3.58% | n/a |
Research and Development Revenue | 248M | 240M | 269M | 242M | 227M | 253M | 240M | 234M | 210M | 175M | 228M | 225M | 244M | 222M | 248M | 254M | 293M | 258M | 225M | 221M | 232M | 240M | 276M | 261M | 295M | 311M | 290M | 317M | 360M | 545M | 486M | 457M | 684M | 663M | 375M | 389M | 446M | 361M | 386M | 332M |
Research and Development Revenue Growth | +3.33% | -10.78% | +11.16% | +6.61% | -10.28% | +5.42% | +2.56% | +11.43% | +20.00% | -23.25% | +1.33% | -7.79% | +9.91% | -10.48% | -2.36% | -13.31% | +13.57% | +14.67% | +1.81% | -4.74% | -3.33% | -13.04% | +5.75% | -11.53% | -5.14% | +7.24% | -8.52% | -11.94% | -33.94% | +12.14% | +6.35% | -33.19% | +3.17% | +76.80% | -3.60% | -12.78% | +23.55% | -6.48% | +16.27% | n/a |
Sales and Marketing Revenue | 650M | 626M | 656M | 608M | 610M | 576M | 603M | 546M | 549M | 539M | 594M | 584M | 632M | 597M | 615M | 585M | 683M | 605M | 597M | 613M | 706M | 595M | 666M | 648M | 797M | 743M | 710M | 771M | 865M | 860M | 960M | 971M | 1.13B | 940M | 952M | 839M | 916M | 780M | 860M | 922M |
Sales and Marketing Revenue Growth | +3.83% | -4.57% | +7.89% | -0.33% | +5.90% | -4.48% | +10.44% | -0.55% | +1.86% | -9.26% | +1.71% | -7.59% | +5.86% | -2.93% | +5.13% | -14.35% | +12.89% | +1.34% | -2.61% | -13.17% | +18.66% | -10.66% | +2.78% | -18.70% | +7.27% | +4.65% | -7.91% | -10.87% | +0.58% | -10.42% | -1.13% | -13.99% | +20.11% | -1.26% | +13.47% | -8.41% | +17.44% | -9.30% | -6.72% | n/a |